Nano-X Imaging Ltd. NNOX Securities Class Action Lawsuit Update

• Company: Nano-X Imaging Ltd. (NASDAQ: NNOX)
• Lead Plaintiff Deadline: August 11, 2026
• Class Period: March 31, 2025 - April 17, 2026
• Stock Drop: April 20, 2026 - NNOX fell $0.695 (24.39%) to $2.155

On June 12, 2026, a securities class action complaint was filed in the United States District Court for the District of New Jersey against Nano-X Imaging Ltd. (NASDAQ: NNOX), its Chief Executive Officer Erez Meltzer, and its Chief Financial Officer Ran Daniel, who according to the complaint was announced to step down effective July 31, 2026. The lawsuit covers a class period from March 31, 2025 through April 17, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Throughout 2025, Nano-X's leadership painted a picture of a company on the rise. CEO Meltzer told investors of "accelerated" U.S. commercialization, a "robust" pipeline, a sales funnel that had "doubled," and the "diligent execution" of a multifaceted growth strategy. CFO Daniel assured analysts that operating expenses were under control, that efficiencies were being wrung from the business, and that revenue would soon "alleviate" the cash burn. Quarter after quarter, Nano-X's releases reported the carrying value of the company's property and equipment, including assets tied to its manufacturing base. In November 2025, while the complaint alleges the stock was inflated by these statements, Nano-X sold over 3.8 million shares to an institutional investor, raising $15 million.

The narrative collapsed on April 20, 2026. In a pre-market press release announcing Q4 2025 results, Nano-X disclosed a $33.4 million net loss, driven by a $17.5 million impairment charge tied to a sweeping restructuring of the very Korean manufacturing operations its leaders had championed. The company acknowledged it needed to "shift to a more efficient outsourced production model that is better aligned with current and anticipated demand," a stark reversal of months of optimistic messaging. The same announcement revealed that Daniel would step down as CFO. Investors reacted swiftly: NNOX shares plunged $0.695 per share, or 24.39%, to close at $2.155.

Backdrop and Business Context

Nano-X Imaging Ltd. was incorporated in Israel on December 20, 2018. According to Nano-X's IPO prospectus, the company's technology has roots in field-emission display technology originally developed by Sony with other technology partners before scientists associated with FET Japan applied related expertise to non-display applications, including X-ray source technology. In August 2020, Nano-X listed on the Nasdaq Global Market under the ticker NNOX, pricing its initial public offering at $18.00 per share, selling approximately 10.6 million ordinary shares (including the fully exercised overallotment option), and raising roughly $190 million in gross proceeds.

Nano-X develops a commercial-grade tomographic imaging device called the Nanox.ARC, a multi-source 3D tomosynthesis system built around a proprietary silicon-based cold-cathode X-ray source. The company also operates a teleradiology services division (through USARAD Holdings), an AI diagnostics suite (Nanox.AI) with multiple FDA-cleared algorithms for analyzing CT scans, and a cloud-based imaging platform (Nanox.CLOUD). Teleradiology remains its largest revenue contributor, generating roughly $3.1 million of the company's $3.7 million in Q4 2025 revenue. For the full year 2025, total revenue was approximately $13.0 million. Nano-X competes in a medical imaging market dominated by multibillion-dollar incumbents such as GE HealthCare, Siemens Healthineers, and Philips.

The company's strategy depends on scaling production of its proprietary MEMs X-ray chips, which during the class period were manufactured at a self-owned fabrication facility in South Korea. According to the complaint, this dependency on in-house Korean chip manufacturing became the fault line at the center of the lawsuit, as the facility's operating costs and production volumes were allegedly misaligned with actual demand for Nano-X's products.

Promises Made vs. Reality

From the very first day of the class period, Nano-X's leadership projected confidence in the company's operational trajectory. On March 31, 2025, in a press release announcing Q4 2024 results, CEO Meltzer touted Nano-X's "accelerated" U.S. commercialization effort and cited "operational progress in 2024, coupled with a growing and innovative portfolio." He characterized the company's commercial rollout as a "strategic approach" underscored by "targeted installations and phased scaling," describing it as a "disciplined path to sustainable growth." When an analyst pressed on whether there had been any material changes to the company's manufacturing channels, Meltzer was unequivocal: "No," he stated, assuring the audience that both the Korean and Swiss manufacturing facilities were actively building capacity. CFO Daniel, asked about operating expense trends for 2025, offered a similarly benign forecast, telling analysts that aside from currency fluctuations, "everything is in line" and "it's more of the same."

As quarters progressed, the messaging only intensified. The 2024 annual report on Form 20-F, filed with the SEC on April 9, 2025, stated that Nano-X had "optimized the MEMs proprietary manufacturing process" and "commenced manufacture of the MEMs X-ray chips at our fabrication facility in Korea, which is expected to meet our currently anticipated manufacturing needs." By the Q1 2025 earnings call in May, Meltzer reported that the sales pipeline had "doubled since January 2025," that the sales team was handling "over 1,000 leads," and that over 60 Nanox.ARC units were in various stages of deployment. He told investors the company was "delivering what we promised" and "making progress all the time" on product costs. In August, the Q2 update described a "growing and increasingly robust commercial pipeline" and a "breakthrough in the European market." Daniel assured an analyst that the company was maintaining operating expenses at steady levels through "more efficiencies and more measurements," promising that revenue growth in the second half of 2025 would produce "a decrease in the operating loss and the burn."

The crescendo came in November 2025. Meltzer described "significant progress across our three strategic growth pillars," including "improved operational efficiency." He declared that Nano-X was "building a leaner, more focused organization" and remained "dedicated to accelerating and development of a highly efficient manufacturing operation." Notably, even as he spoke of extracting efficiencies from manufacturing, he disclosed no disconnect between the company's production operations and actual demand, no contemplated restructuring, and no looming impairment charges. Days later, while the complaint alleges Nano-X's stock price was artificially inflated by these statements, Nano-X completed a $15 million registered direct offering.

The reality that emerged on April 20, 2026 bore no resemblance to these assurances. Nano-X reported a Q4 2025 net loss of $33.4 million, more than double the prior year's comparable loss, driven by a $17.5 million impairment charge on its Korean chip manufacturing facility. The company announced it would close the chip manufacturing line in South Korea, downsize fabrication facilities, and transfer production to third-party partners, expecting total restructuring charges of approximately $18.0 million. Meltzer himself acknowledged the need "to reduce our Korean operation's OpEx and cash burn and improve efficiency" and to "transition to a more efficient outsourced production model better aligned with current and projected demand." As alleged in the complaint, the defendants' repeated assurances of manufacturing optimization, operational efficiency, and demand-driven scaling were materially false and misleading, concealing the reality that Nano-X's production operations were poorly aligned with demand, that operating expenses and cash burn were significantly elevated, and that the risk of disruptive restructuring and impairment charges had materially increased.

Timeline of Alleged Misconduct and Disclosures

Class Period: March 31, 2025 - April 17, 2026, inclusive.

March 31, 2025: Class period opens. Nano-X issues press release announcing Q4 2024 results. CEO Meltzer touts "accelerated" U.S. commercialization, "operational progress," and confidence in market positioning. Company reports $45.4 million in property and equipment.

March 31, 2025: Nano-X hosts investor conference call. Meltzer describes a "robust" pipeline, "growing customer base," and "disciplined path to sustainable growth." States no material changes to manufacturing channels. CFO Daniel says operating expenses are "more of the same."

April 9, 2025: Nano-X files 2024 annual report (Form 20-F) with the SEC. Reports optimized MEMs manufacturing process, Korean facility "expected to meet currently anticipated manufacturing needs." Individual Defendants sign Sarbanes-Oxley certifications attesting to the accuracy of the filing.

May 22, 2025: Nano-X announces Q1 2025 results. Meltzer states sales pipeline has "doubled since January 2025," with over 1,000 leads and over 60 Nanox.ARC units in various deployment stages. Reports $45.3 million in property and equipment.

August 12, 2025: Nano-X announces Q2 2025 results. Company describes a "growing and increasingly robust commercial pipeline" and a European market "breakthrough." Daniel assures analysts that operating expenses are being maintained through efficiencies. Reports $46.1 million in property and equipment.

November 20, 2025: Nano-X announces Q3 2025 results. Meltzer describes "significant progress" in operational efficiency, states company is "dedicated to accelerating and development of a highly efficient manufacturing operation." Reports $46.8 million in property and equipment.

November 23, 2025: Nano-X announces a registered direct offering of approximately 3.83 million ordinary shares.

November 25, 2025: The offering closes; Nano-X raises $15 million in gross proceeds.

April 20, 2026: Alleged Corrective Disclosure. Nano-X announces Q4 2025 results, reporting a $33.4 million net loss including a $17.5 million impairment charge from restructuring its Korean chip manufacturing facility.

Company discloses plan to close chip manufacturing line in South Korea, downsize facilities, and shift to outsourced production. Meltzer acknowledges need to "reduce our Korean operation's OpEx and cash burn." CFO Daniel's departure announced effective July 31, 2026.

April 20, 2026: NNOX shares fall $0.695 per share, or 24.39%, to close at $2.155.

April 21, 2026: Ladenburg Thalmann lowers price target on NNOX to $9.60 from $10.60, citing the $17.5 million impairment and CFO replacement.

Investor Harm and Market Reaction

According to the complaint, the April 20, 2026 alleged corrective disclosure was followed by a severe and immediate market reaction. NNOX shares fell $0.695 per share, or 24.39%, closing at $2.155 on the day the company revealed the $17.5 million impairment charge and Korean facility restructuring. Seeking Alpha reported that morning that shares had lost approximately 17% in early trading, noting the stock was "on track to what could be its worst intraday decline in over two years." The losses deepened throughout the session as investors absorbed the magnitude of the reversal: a net loss of $33.4 million for Q4 2025, representing a 137% year-over-year surge, driven largely by the write-down of manufacturing assets the defendants had repeatedly described in positive terms.

The complaint also cites the following day’s analyst reaction: Ladenburg Thalmann cut its price target on NNOX to $9.60 from $10.60, citing the impairment, the restructuring commentary, and the announced CFO departure. For investors who purchased NNOX during the class period, when the complaint alleges the stock price was inflated by statements concerning manufacturing efficiency, robust demand, and controlled expenses, the April 20 disclosure was followed by a 24.39% decline in NNOX’s share price. Notably, Nano-X had completed a $15 million equity offering just five months earlier, in November 2025, while the stock was still allegedly inflated by the challenged statements. The complaint alleges that investors who purchased or otherwise acquired Nano-X securities during the class period and were damaged upon the alleged corrective disclosures suffered losses.

Litigation & Procedural Posture

The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all Defendants, and under Section 20(a) of the Exchange Act against the Individual Defendants as controlling persons of Nano-X.

The defendants are Nano-X Imaging Ltd., CEO Erez Meltzer (who also serves as Acting Chairman), and CFO Ran Daniel.

Scienter allegations center on the defendants' motive and opportunity to commit fraud, as well as their actual knowledge or reckless disregard for the truth. The complaint alleges that the Individual Defendants were highly focused on manufacturing efficiency throughout the class period, making repeated, specific representations about these efforts in earnings releases and conference calls, and were therefore "undoubtedly aware" that production operations were misaligned with demand and that the company faced unsustainable operating expenses and cash burn. The complaint further alleges corporate scienter through the November 2025 equity offering, in which Nano-X sold approximately 3.83 million ordinary shares and raised $15 million at allegedly inflated prices. No insider stock sales by Individual Defendants are specifically alleged, and no confidential witnesses are cited.

The complaint was filed on June 12, 2026 and the case is in its early stages. The complaint seeks class certification under Federal Rule of Civil Procedure 23(a) and (b)(3) on behalf of all persons who purchased or acquired Nano-X securities during the class period and were damaged by the alleged corrective disclosures. Lead plaintiff submissions are due August 11, 2026.

SEC Filings & Risk Factors

Throughout the class period, Nano-X's SEC filings projected a narrative of manufacturing optimization and operational discipline while allegedly omitting material adverse information about the misalignment between its production operations and actual demand.

The 2024 annual report on Form 20-F, filed on April 9, 2025, stated that Nano-X had "optimized the MEMs proprietary manufacturing process" and "commenced manufacture of the MEMs X-ray chips at our fabrication facility in Korea, which is expected to meet our currently anticipated manufacturing needs." The filing further represented that the company had "secure[d] additional chip supply in anticipation of commercialization scale up and acceleration of manufacturing activity." Regarding asset impairment, the 20-F disclosed only a $0.2 million charge from 2022 and stated that no impairment charge related to definite life intangible assets had been recorded in 2024, 2023, or 2022. Appended to the filing were Sarbanes-Oxley certifications signed by both Meltzer and Daniel, attesting that the report contained no untrue statements of material fact, no omissions necessary to avoid misleading investors, and that the financial statements "fairly present in all material respects" the company's financial condition.

Quarterly press releases throughout the class period consistently reported the carrying value of Nano-X's property and equipment between $45.3 million and $46.8 million, increasing to $46.8 million as of September 30, 2025. These disclosures reported the carrying value of the company's property and equipment without indicating that a significant impairment would follow.

The complaint alleges that these filings violated Item 105 of SEC Regulation S-K, which required Nano-X to disclose under the heading "Risk Factors" any material factors making an investment in the company speculative or risky. The misalignment between production operations and demand, and the resulting elevated operating expenses and cash burn, allegedly constituted material risk factors. Additionally, the complaint alleges violations of Item 303 of Regulation S-K, which required Nano-X to describe "any known trends or uncertainties" reasonably likely to have a material unfavorable impact on revenues or income from continuing operations. The eventual $17.5 million impairment charge associated with the Korean fabrication facility's chip manufacturing line revealed what the complaint alleges were known trends or uncertainties, not merely generic risks. The corrective Q4 2025 disclosure acknowledged the need to "transition away from certain manufacturing activities" in South Korea, "close its chip manufacturing line," and "downsize its fabrication facilities," with total expected restructuring charges of approximately $18.0 million. The gap between the confident, asset-appreciating narrative in the periodic filings and the abrupt, large-scale restructuring disclosed in April 2026 forms the core of the complaint's disclosure failure allegations.

How to Check Whether You May Be Eligible in the Nano-X Imaging (NNOX) Class Action

• Confirm you purchased NNOX securities during the March 31, 2025 to April 17, 2026 class period
• Review the allegations and eligibility requirements in the pending securities class action
• Gather trade confirmations and brokerage records documenting purchases or losses
• Consult counsel regarding lead plaintiff deadlines, eligibility, and any potential recovery rights

Disclaimer: Attorney Advertising. This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.